However, proteasome inhibitors bortezomib, carfilzomib, and ixazomib have been shown to increase PD-L1 and PD-L2 levels in MM and compromise the anti-myeloma effect of CD8+ T cells [34]. This evidence concerns the gene CD274 and Miyoshi myopathy.